Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma

Enrico P. Spugnini, Irene Cardillo, Alessandra Verdina, Stefania Crispi, Silvia Saviozzi, Raffaele Calogero, Angela Nebbioso, Lucia Altucci, Giancarlo Cortese, Rossella Galati, Jeremy Chien, Viji Shridhar, Bruno Vincenzi, Gennaro Citro, Francesco Cognetti, Ada Sacchi, Alfonso Baldi

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Purpose: The aim of the present study was to evaluate the effects of piroxicam, a widely used nonsteroidal anti-inflammatory drug, alone and in combination with cisplatin (CDDP), on cell growth of mesothelioma cells. Experimental Design: Cell proliferation, cell cycle analysis, and microarray technology were done on MSTO-211H and NCI-H2452 cells treated with piroxicam. Moreover, the effects of piroxicam and CDDP on tumor growth and survival of mouse xenograft models of mesothelioma were determined. Results: Piroxicam treatment of MSTO-211H and NCI-H2452 cells resulted in a significant inhibition of proliferation. Cell cycle analysis revealed that there was an increase in the rate of apoptosis in MSTO-211H cells and an increase in the cells accumulating in G 2-M in NCI-H2452. Moreover, a marked tumor growth inhibition and an extended survival of mice treated with a combination of piroxicam and CDDP in MSTO-211H cell - induced peritoneal mesotheliomas was observed. Last, GeneChip array analysis of MSTO-211H mesothelioma cell line revealed that piroxicam treatment caused up-regulation of metabolic pathway - associated genes and down-regulation of genes related to RNA processing apparatus. Of note, epidermal growth factor receptor, one of the new biological targets of chemotherapy for mesothelioma, was down-regulated and HtrA1, a serine protease recently shown to be an endogenous mediator of CDDP cytotoxicity, was up-regulated following piroxicam treatment both in vitro and in vivo. Conclusion: These data suggest that piroxicam sensitizes mesothelioma cells to CDDP-induced cytotoxicity by modulating the expression of several target genes. Therefore, piroxicam in combination with CDDP might potentially be useful in the treatment of patients with mesothelioma.

Original languageEnglish (US)
Pages (from-to)6133-6143
Number of pages11
JournalClinical Cancer Research
Issue number20 PART 1
StatePublished - Oct 15 2006

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma'. Together they form a unique fingerprint.

Cite this